Therapeutic potential of anti-vascular endothelial growth factor (anti-VEGF) agents in orbital lymphangioma
Orbital lymphangiomas are non encapsulated tumors and one of the most common vascular tumors in children. Surgery indicated for selected patients but complete resection of tumors is difficult due to their diffuse infiltration within adjacent tissues. Carbon dioxide, contact Nd:YAG lasers and percutaneous sclerotherapy as an alternative to surgical resection have variable success. Challenge continues to be to find a safe and effective therapeutic modality for this purpose. There are many data supporting a casual role for vascular endothelial growth factor (VEGF) in lymphangiogenesis. One possible strategy for treating orbital lymphangioma is to inhibit VEGF activity by competitively binding VEGF with a specific neutralizing anti-VEGF antibody. The vitreo-retinal service in the recent years enjoyed a high level of success in managing diabetic retinopathy, choroidal neovascularization, and neovascular glaucoma using anti-VEGF strategies. Efficacy and tolerability have been demonstrated for drugs targeting VEGF. We herein hypothesize that intralesional application of anti-VEGF agents such as pegaptanib, ranibizumab and bevacizumab are potentially useful for treating orbital lymphangioma and preventing its complications. Further investigations are needed to place this mode of treatment alongside orbital lymphangioma therapeutics.
Journal of Medical Hypotheses and Ideas, Volume:2 Issue:2, 2008
روش‌های دسترسی به متن این مطلب
اشتراک شخصی
در سایت عضو شوید و هزینه اشتراک یک‌ساله سایت به مبلغ 300,000ريال را پرداخت کنید. همزمان با برقراری دوره اشتراک بسته دانلود 100 مطلب نیز برای شما فعال خواهد شد!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی همه کاربران به متن مطالب خریداری نمایند!